The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - AADi; Alkermes; Artios; AstraZeneca; Bayer; Kadmon; Merck; Mersana; Novartis; Pfizer/EMD Serono; Repare Therapeutics; Tesaro; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); tesaro (Inst)
 
Elizabeth Katherine Lee
Consulting or Advisory Role - AADi
Research Funding - AADi (Inst); KSQ Therapeutics (Inst); Merck (Inst); Repare Therapeutics (Inst); Seagen (Inst)
 
SuChun Cheng
No Relationships to Disclose
 
Alexandre Andre B. A. Da Costa
No Relationships to Disclose
 
Andrea Elisabeth Wahner Hendrickson
Consulting or Advisory Role - Oxcia
Speakers' Bureau - OncLive
Research Funding - Amgen (Inst); ProLynx (Inst)
Patents, Royalties, Other Intellectual Property - TORL Therapeutics (Inst)
 
Doga Gulhan
Patents, Royalties, Other Intellectual Property - A provisional patent application is being drafted regarding an algorithm developed by the author for which a coversheet provisional has been filed on September 24, 2018 titled “Computational method to identify mutational signatures from sequencing data”. (Inst)
 
Bose Kochupurakkal
No Relationships to Disclose
 
David Kolin
Stock and Other Ownership Interests - Abbott Laboratories; Alcon; Becton Dickinson; Novartis; Pfizer; UnitedHealthcare; Viatris
 
Elise C. Kohn
No Relationships to Disclose
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Regeneron (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)
 
Elizabeth Stover
Patents, Royalties, Other Intellectual Property - Patent pending
 
Jennifer Curtis
No Relationships to Disclose
 
Hannah Sawyer
No Relationships to Disclose
 
Madeline Polak
No Relationships to Disclose
 
Dipanjan Chowdhury
No Relationships to Disclose
 
Anniina Färkkilä
Speakers' Bureau - AstraZeneca
Research Funding - GlaxoSmithKline (Inst)
 
Alan D. D'Andrea
Consulting or Advisory Role - EMD Serono
 
Geoffrey Shapiro
Consulting or Advisory Role - Artios; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Fusion Pharmaceuticals; ImmunoMet; Janssen Oncology; Kymera; Lilly; Merck Serono; Pfizer; Syros Pharmaceuticals; Xinthera; Zentalis
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Biosplice (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb/Medarex (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Cyclacel (Inst); Cyteir (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
 
Ursula A. Matulonis
Honoraria - Advaxis; Alkermes; Symphogen
Consulting or Advisory Role - 2X Oncology; Agenus; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; GlaxoSmithKline; Immunogen; Merck; NextCure; Novartis; Trillium Therapeutics
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca